Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376133764> ?p ?o ?g. }
- W4376133764 endingPage "2742" @default.
- W4376133764 startingPage "2730" @default.
- W4376133764 abstract "Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical antifibrotic activity and no dose-limiting toxicities in phase I trials. We report results from stage 1 of a phase II trial of zinpentraxin alfa in patients with intermediate-1/2 or high-risk MF. Patients (n=27) received intravenous zinpentraxin α weekly (QW) or every 4 weeks (Q4W), as monotherapy or an additional therapy for patients on stable-dose ruxolitinib. The primary endpoint was overall response rate (ORR; investigatorassessed) adapted from International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria. Secondary endpoints included modified Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) change, bone marrow (BM) MF grade reduction, pharmacokinetics, and safety. ORR at week 24 was 33% (n=9/27) and varied across individual cohorts (QW: 38% [3/8]; Q4W: 14% [1/7]; QW+ruxolitinib: 33% [2/6]; Q4W+ruxolitinib: 50% [3/6]). Five of 18 evaluable patients (28%) experienced a ≥50% reduction in MPN-SAF TSS, and six of 17 evaluable patients (35%) had a ≥1 grade improvement from baseline in BM fibrosis at week 24. Most treatment-emergent adverse events (AE) were grade 1–2, most commonly fatigue. Among others, anemia and thrombocytopenia were infrequent (n=3 and n=1, respectively). Treatment-related serious AE occurred in four patients (15%). Overall, zinpentraxin alfa showed evidence of clinical activity and tolerable safety as monotherapy and in combination with ruxolitinib in this open-label, non-randomized trial (clinicaltrials gov. Identifier: NCT01981850)." @default.
- W4376133764 created "2023-05-12" @default.
- W4376133764 creator A5004674303 @default.
- W4376133764 creator A5008109253 @default.
- W4376133764 creator A5009131648 @default.
- W4376133764 creator A5014362126 @default.
- W4376133764 creator A5021279357 @default.
- W4376133764 creator A5028418409 @default.
- W4376133764 creator A5028483626 @default.
- W4376133764 creator A5039057642 @default.
- W4376133764 creator A5046597302 @default.
- W4376133764 creator A5064969470 @default.
- W4376133764 creator A5065621786 @default.
- W4376133764 creator A5066614305 @default.
- W4376133764 creator A5067214379 @default.
- W4376133764 creator A5072336042 @default.
- W4376133764 creator A5078887304 @default.
- W4376133764 creator A5079394652 @default.
- W4376133764 creator A5080561627 @default.
- W4376133764 creator A5082838869 @default.
- W4376133764 creator A5085521139 @default.
- W4376133764 creator A5086269584 @default.
- W4376133764 date "2023-05-11" @default.
- W4376133764 modified "2023-10-14" @default.
- W4376133764 title "Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial" @default.
- W4376133764 cites W1534089060 @default.
- W4376133764 cites W1558211123 @default.
- W4376133764 cites W1633651668 @default.
- W4376133764 cites W1967763945 @default.
- W4376133764 cites W1973054660 @default.
- W4376133764 cites W2000906310 @default.
- W4376133764 cites W2006652270 @default.
- W4376133764 cites W2008799537 @default.
- W4376133764 cites W2010298229 @default.
- W4376133764 cites W2014091629 @default.
- W4376133764 cites W2021443159 @default.
- W4376133764 cites W2053666216 @default.
- W4376133764 cites W2056278417 @default.
- W4376133764 cites W2081253240 @default.
- W4376133764 cites W2103208579 @default.
- W4376133764 cites W2115351357 @default.
- W4376133764 cites W2121743767 @default.
- W4376133764 cites W2127559749 @default.
- W4376133764 cites W2129475142 @default.
- W4376133764 cites W2139011653 @default.
- W4376133764 cites W2149055075 @default.
- W4376133764 cites W2165360615 @default.
- W4376133764 cites W2166552844 @default.
- W4376133764 cites W2279123099 @default.
- W4376133764 cites W2310526643 @default.
- W4376133764 cites W2339658711 @default.
- W4376133764 cites W2402386382 @default.
- W4376133764 cites W2405712018 @default.
- W4376133764 cites W2416281109 @default.
- W4376133764 cites W2493190817 @default.
- W4376133764 cites W2514287253 @default.
- W4376133764 cites W2559836007 @default.
- W4376133764 cites W2583102591 @default.
- W4376133764 cites W2589237569 @default.
- W4376133764 cites W2622547803 @default.
- W4376133764 cites W2771403719 @default.
- W4376133764 cites W2782417153 @default.
- W4376133764 cites W2791240656 @default.
- W4376133764 cites W2804909402 @default.
- W4376133764 cites W2807352275 @default.
- W4376133764 cites W2896540448 @default.
- W4376133764 cites W2945737656 @default.
- W4376133764 cites W2982191534 @default.
- W4376133764 cites W2995010510 @default.
- W4376133764 cites W2996087467 @default.
- W4376133764 cites W3010774459 @default.
- W4376133764 cites W3032214830 @default.
- W4376133764 cites W3181435917 @default.
- W4376133764 cites W3184692155 @default.
- W4376133764 cites W4281250546 @default.
- W4376133764 doi "https://doi.org/10.3324/haematol.2022.282411" @default.
- W4376133764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37165840" @default.
- W4376133764 hasPublicationYear "2023" @default.
- W4376133764 type Work @default.
- W4376133764 citedByCount "4" @default.
- W4376133764 countsByYear W43761337642023 @default.
- W4376133764 crossrefType "journal-article" @default.
- W4376133764 hasAuthorship W4376133764A5004674303 @default.
- W4376133764 hasAuthorship W4376133764A5008109253 @default.
- W4376133764 hasAuthorship W4376133764A5009131648 @default.
- W4376133764 hasAuthorship W4376133764A5014362126 @default.
- W4376133764 hasAuthorship W4376133764A5021279357 @default.
- W4376133764 hasAuthorship W4376133764A5028418409 @default.
- W4376133764 hasAuthorship W4376133764A5028483626 @default.
- W4376133764 hasAuthorship W4376133764A5039057642 @default.
- W4376133764 hasAuthorship W4376133764A5046597302 @default.
- W4376133764 hasAuthorship W4376133764A5064969470 @default.
- W4376133764 hasAuthorship W4376133764A5065621786 @default.
- W4376133764 hasAuthorship W4376133764A5066614305 @default.
- W4376133764 hasAuthorship W4376133764A5067214379 @default.
- W4376133764 hasAuthorship W4376133764A5072336042 @default.
- W4376133764 hasAuthorship W4376133764A5078887304 @default.
- W4376133764 hasAuthorship W4376133764A5079394652 @default.